US approval in 1Q 2010 = 500% Potential !!!!!!!!!!!!!!!!

[BiotechMaster]

FDA approval and Pivotal results coming very soon !! This stock has tremendous upside potential ! GET IN NOW BEFORE ITS TOO LATE !!!!

Intellipharmaceutics (IPCI)

Market Cap : 30 Mio$
Cash : 10 Mio$
Price : 1,72 $

Shares Out : 16,9 M


Huge Pipeline

Product (Country) Type Status

Product I (USA) ANDA Filed with FDA

Product II (USA) ANDA Awaiting results of Pivotal Clinical Studies

Product III (USA) ANDA Scaled-up, Submission batched manufactured; Undergoing stability
studies; Pivotal. bioequivalence studies have commenced

Product IV (USA) ANDA Scaled-up, Submission batched manufactured; Undergoing stability
studies; Pivotal bioequivalence Studies have commenced

Product V (USA) ANDA Scaled-up, Submission batched manufactured; Undergoing stability
studies.

Product VI (USA) ANDA Scaled-up, Submission batched manufactured; Undergoing stability
studies.

Product VII (USA) ANDA Scale up

Product VIII (USA) ANDA Scale Up

Product IX (USA) NDA Production for further Bioavailability Studies

Product X (USA) NDA Bioavailability Studies; Consulting with FDA

Product XI (USA) ANDA Formulation

Product XII (USA) ANDA Formulation

Product XIII (USA) ANDA Formulation

Product XIV (USA) NDA Pre-formulation

Product XV (USA) NDA Pre-formulation






Some Small-Cap Biotech Stocks Worth Watching -- Seeking Alpha

Finally, we're hearing chatter that a big fund took a big position in Intellipharmaceutics (IPCI) yesterday. the company has been on a road show and attracting some attention. We're going to try to find out why that is and perhaps arrange an interview with the management team for a future special report.

These funds don't take big positions in the open market like this unless they hear or see something they really like and believe in long-term. Based in Toronto, Ontario, but trading on the Nasdaq, the company reportedly has an impressive and unique drug delivery platform and they are known as a pharmaceutical innovator. Those controlled-release drug delivery technologies are being applied to the development of a wide range of pharmaceuticals. The Company itself has a pipeline of both generic and new drugs.

[BiotechMaster]

Huge Potential here and still flying under radar !!!

IntelliPharmaCeutics is a privately-held specialty pharmaceutical company that is focused on developing and manufacturing new and generic controlled-release pharmaceutical products using its broadly applicable, proprietary delivery technologies. Currently, IntelliPharmaCeutics has 15 product candidates in its development pipeline several of which are partnered with third-party drug companies. IntelliPharmaCeutics' lead product candidates include Dexmethylphenidate XR, a generic version of the marketed drug Focalin XR(R), which is partnered with Par Pharmaceutical and is currently the subject of an Abbreviated New Drug Application (ANDA) filing with the U.S. Food and Drug Administration (FDA), and Carvedilol CR, a generic version of the brand name drug Coreg CR, an internal pipeline product now ready for entry into pivotal bioequivalence studies.



Our lead products in the generic, controlled-release pharmaceutical category are Dexmethylphenidate XR (dexmethylphenidate hydrochloride), a generic version of Focalin XR®, which is an extended-release capsule for the treatment of Attention Deficit Hyperactivity Disorder, and Carvedilol CR (carvedilol phosphate), a generic version of Coreg CR®, which is an extended release capsule for the treatment of high blood pressure. In 2008, Focalin®, including Focalin XR®, had U.S. sales of approximately U.S. $350 million, and Coreg®, including Coreg CR®, had U.S. sales of approximately U.S. $300M million.